Apimeds Pharmaceuticals US Operating Income

Apimeds Pharmaceuticals US (APUS) currently reports a operating income of $-27M as of June 2026. That compares with $-3.6M in the prior-year period — down 658.9% year over year. Use the charts on this page to explore Apimeds Pharmaceuticals US's operating income history and peer comparisons.

Apimeds Pharmaceuticals US's operating income decreased from $-3.6M to $-27M — a 658.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $-27M in operating income as of June 2026. That compares with $-3.6M in the prior-year period — down 658.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.